18 reports

Olysio is indicated for the treatment of hepatitis C genotype ## in combination with PEG/ RBV, while Sovaldi is indicated for use in adults with genotypes ##, ##, ## and ##.

  • Interferon
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group
  • PEGINTERFERON LAMBDA-1A - DRUG PROFILE

The SVR## rate for all genotype ## infected patients in the Lambda/ RBV/ DCV group was ## percent (##/ ##).

  • Interferon
  • United States
  • World
  • Product Initiative
  • REPLICor Inc.
  • PEGINTERFERON LAMBDA-1A - DRUG PROFILE

The SVR## rate for all genotype ## infected patients in the Lambda/ RBV/ DCV group was ##% (##/ ##).

  • Hepatitis
  • Interferon
  • United States
  • Product Initiative
  • REPLICor Inc.
  • interferon alpha - Drug Profile

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Interferon
  • Therapy
  • United States
  • World
  • Product Initiative

## ## ## ## United States ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## CLINICA

  • Drug Development
  • Interferon
  • World
  • Product Initiative
  • Shionogi & Co., Ltd.
  • INO-8000 - DRUG PROFILE
  • N-89 - DRUG PROFILE

IN JAPAN, ABBVIE IS AIMING FOR THE APPROVAL OF AN EIGHT-WEEK TREATMENT REGIMEN FOR GENOTYPE ## AND GENOTYPE ## HEPATITIS C.

  • Hepatitis
  • Interferon
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company
  • MK-6169 - DRUG PROFILE
  • INO-8000 - DRUG PROFILE

The SMC restriction: genotype ## and ## CHC only.

  • Antiviral
  • Hepatitis
  • Interferon
  • Therapy
  • Bristol-Myers Squibb Company

The prominent features of this report are - ##.

  • Clinical Trial
  • Dermatological Condition
  • Interferon
  • Pharmaceutical
  • Merck & Co., Inc.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Conatus Pharmaceuticals Inc ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## Norgine BV ## ## ## ## ## ## ## Otsuka Holdings Co Ltd ## ## ## ## ## ## ## Ocera Therapeutics Inc ##

  • Clinical Trial
  • Digestive System Disorder
  • Interferon
  • Therapy
  • World

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Bristol-Myers Squibb Company ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Bukwang Pharm Co Ltd ## ## ## ## ## ##

  • Hepatitis
  • Infectious Disease
  • Interferon
  • World
  • GlaxoSmithKline plc

Patients were randomized ##:##:## to receive ## mg of emricasan, ## mg of emricasan, or placebo twice daily for ## weeks.

  • Interferon
  • Monoclonal Antibody
  • Pharmaceutical
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Interferon
  • Medical Biotechnology
  • Neurological Disorder
  • Therapy
  • Biogen Idec Inc.
  • interferon alpha - Drug Profile

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Interferon
  • Medical Biotechnology
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 284 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Interferon
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Interferon
  • Neurological Disorder
  • Protein Therapy
  • Biogen Idec Inc.
  • INTERFERON ALFA - DRUG PROFILE

Day ## must start in AM.

  • Interferon
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • BioLineRx Ltd.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Interferon
  • World
  • Product Initiative

Patients will be randomized ##:##:## to receive ## mg of emricasan, ## mg of emricasan, or placebo twice daily for ## weeks.

  • Clinical Trial
  • Drug Development
  • Interferon
  • World
  • Product Initiative